-1651085832.png){kind=logo}
Home
HelpTest Code DHTS Dihydrotestosterone, Serum
Additional Codes
CNE Order Code: Dihydrotestosterone (DHT)
Reporting Name
Dihydrotestosterone, SUseful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Testing Algorithm
For more information see Steroid Pathways.
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 90 days | ||
| Ambient | 28 days |
Special Instructions
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
|
Mean |
Age |
Reference range (pg/mL) |
|
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
|
Stage II |
12.1 years |
≤200 |
|
Stage III |
13.6 years |
80-330 |
|
Stage IV |
15.1 years |
220-520 |
|
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
|
Mean |
Age |
Reference range (pg/mL) |
|
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
|
Stage II |
10.5 years |
≤300 |
|
Stage III |
11.6 years |
≤300 |
|
Stage IV |
12.3 years |
≤300 |
|
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Day(s) Performed
Monday, Wednesday, Friday
CPT Code Information
82642
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| DHTS | Dihydrotestosterone, S | 1848-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 81479 | Dihydrotestosterone, S | 1848-1 |
Interpretation
Patients taking 5-alpha reductase inhibitor have decreased dihydrotestosterone (DHT) serum levels.
Patients with genetic 5-alpha reductase deficiency (a rare disease) also have reduced DHT serum levels.
DHT should serve as the primary marker of peripheral androgen production. However, because it is metabolized rapidly and has a very high affinity for sex hormone-binding globulin, DHT does not reflect peripheral androgen action. Instead, its distal metabolite, 3-alpha, 17-beta-androstanediol glucuronide, serves as a better marker of peripheral androgen action.
For more information see Steroid Pathways.
Report Available
2 to 8 daysReject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics